From what age is Humira (adalimumab) indicated for severe chronic plaque psoriasis in children who have not responded adequately to, or are unsuitable for, topical therapy and phototherapy?

Humira (adalimumab) is indicated from 4 years of age for severe chronic plaque psoriasis in children and adolescents who have responded inadequately to, or are unsuitable for, topical therapy and phototherapies.